Improving lives by advancing immuno-oncology treatments
At NewLink Genetics, our commitment is simple and passionate: we’re focused on discovering, developing and commercializing novel immuno-oncology products because we believe they are the future of cancer treatment.
Through science, clinical trials and future opportunities, immuno-oncology treatments will help improve the lives of cancer patients. Much of the focus in our research and development is on indoleamine 2,3-dioxygenase (IDO). IDO is an increasingly validated immuno-oncology target. Two promising IDO pathway inhibitors, one of which we are developing in conjunction with Genentech/Roche*, is GDC-0919 and our proprietary IDO pathway inhibitor named Indoximod. These are differentiated by two distinct mechanisms of action.
GDC-0919 targets the enzyme directly, while Indoximod inhibits the effects of IDO by supplying a “tryptophan-sufficiency” signal. Since IDO is a central pathway in tumor immuno-oncology, it is potentially applicable across a wide range of malignancies. In our estimation, continued success in clinical programs targeting the IDO pathway in treating melanoma, brain and pancreatic cancers, may support multiple indications in the near future.
Germane to discovering new immuno-oncology treatments, our scientific vision includes “over-the-horizon” programs, such as PTEN, that can help modulate the function of regulatory T cells (Tregs). Considering that an important goal of tumor immunotherapy is to identify and modulate tumor microenvironment conditions and pathways that control Tregs, several studies are revealing that PTEN is one of the critical molecules that regulate the function of Tregs. Similar to IDO and PD-1, the PTEN pathway in Tregs could be a critical target to disrupt tumor